Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.
You may also be interested in...
Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC
Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.
Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC
Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.
Sunesis: Top-Line Phase II Data Positive In Ovarian Cancer
Early results generate interest from would-be partners, company tells “The Pink Sheet” DAILY.